Merrill Downgrades Biogen Rating

Analyst Eric Hecht is concerned that a rival's multiple sclerosis drug will be highly competitive

Merrill Lynch downgraded its investment recommendation on Biogen Corp. (BGEN ) to near-term and long-term neutral from accumulate.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.